Rapid Virological Response (RVR) of Daclatasvir and Sofosbuvir Plus Ribavirin in Non-Cirrhotic, Treatment-Naive Patients of Hepatitis C Virus Genotype 3

Rapid Virological Response (RVR) of Daclatasvir and Sofosbuvir Plus Ribavirin in Non-Cirrhotic, Treatment-Naive Patients of Hepatitis C Virus Genotype 3

Background :To determine the efficacy of Daclatasvir and Sofosbuvir plus Ribavirin in achieving Rapid Virological Response (RVR) in patients of Hepatitis C genotype 3 who are non-cirrhotic and have not received any previous treatment. Methods: In this descriptive case series study, 100 non cirrhoti...

Full description

Bibliographic Details
Main Authors:	Muhammad Sarfraz, Arshad Rabbani, Muhammad Shahzad Manzoor, Zubair Ahmed, Ali Hassan
Format:	Article
Language:	English
Published:	Rawalpindi Medical University 2018-12-01
Series:	Journal of Rawalpindi Medical College
Subjects:	HCV Genotype 3 RVR Oral Direct Acting Antivirals DAA Daclatasvir
Online Access:	https://www.journalrmc.com/index.php/JRMC/article/view/950

Similar Items

VIROLOGICAL RESPONSES OF VELPATASVIR/SOFOSBUVIR IN PATIENTS WITH HCV GENOTYPE 3
by: Muhammad Sarfraz, et al.
Published: (2020-03-01)

Hemodialysis Patients Treated for Hepatitis C Using a Sofosbuvir-based Regimen
by: Sanjay Kumar Agarwal, et al.
Published: (2017-09-01)

Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: a large, field-practice study
by: Rodolfo Sacco, et al.
Published: (2020-12-01)

Daclatasvir plasma level and resistance selection in HIV patients with hepatitis C virus cirrhosis treated with daclatasvir, sofosbuvir, and ribavirin
by: Saverio G. Parisi, et al.
Published: (2016-08-01)

Safety and efficacy of directly acting antivirals (sofosbuvir and daclatasvir) in treatment of chronic HCV in HIV-HCV co-infected Egyptian patients
by: Inas E L-Khedr Mohamed, et al.
Published: (2021-04-01)

A mini-review on sofosbuvir and daclatasvir treatment in coronavirus disease 2019
by: M. Shabani, et al.
Published: (2021-07-01)

Prevalence and predictors of occult hepatitis C virus infection among Egyptian patients who achieved sustained virologic response to sofosbuvir/daclatasvir therapy: a multi-center study
by: Mekky MA, et al.
Published: (2019-01-01)

A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients
by: Michael Duerr, et al.
Published: (2019-02-01)

Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus
by: Phil McEwan, et al.
Published: (2017-07-01)

TREATMENT OF HCV INFECTION BY A COMBINATION OF SOFOSBUVIR AND DACLATASVIR
by: Y. O. SHULPEKOVA, et al.
Published: (2017-05-01)

Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C
by: Andrew Hill, et al.
Published: (2016-01-01)

Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis
by: Sperl J, et al.
Published: (2017-06-01)

Resistance Mutations A30K and Y93N Associated with Treatment Failure with Sofosbuvir and Daclatasvir for Hepatitis C Virus Infection Non-Responder Patients: Case Reports
by: Vanessa D. Costa, et al.
Published: (2019-10-01)

Sustained virological response 12 versus sustained virological response 24 as evaluation endpoints in chronic hepatitis C virus Egyptian patients treated with sofosbuvir-based regimens
by: Maha M Elsabaawy, et al.
Published: (2019-01-01)

Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan
by: Saima Mushtaq, et al.
Published: (2020-09-01)

Daclatasvir–sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life
by: Pol S, et al.
Published: (2016-03-01)

Resistance Patterns Associated with HCV NS5A Inhibitors Provide Limited Insight into Drug Binding
by: Moheshwarnath Issur, et al.
Published: (2014-11-01)

Effect of sofosbuvir plus daclatasvir on virological response and liver function tests as a line of treatment for HCV related cirrhosis (a prospective cohort study)
by: Omaima Mohamed Ali, et al.
Published: (2020-07-01)

SVR 24 Achievement Two Weeks After a Tripled Dose of Daclatasvir in an HCV Genotype 3 Patient
by: Sara Lo Menzo, et al.
Published: (2018-07-01)

Safety and Efficacy of Sofosbuvir and Daclatasvir in The Treatment of Chronic HCV Infection in Elderly Egyptian Patients
by: Mohamed G. Mohamed, et al.
Published: (2021-01-01)

Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection
by: Ahmed OA, et al.
Published: (2018-03-01)

Curing Chronic Hepatitis C: A Cost Comparison of the Combination Simeprevir Plus Sofosbuvir vs. Protease-Inhibitor-Based Triple Therapy
by: Jacob A. Langness, et al.
Published: (2017-05-01)

Efficacy and safety of daclatasvir-containing regimens in the treatment of chronic hepatitis C patients in Damietta
by: Alaa Eldeen M Hashim, et al.
Published: (2020-01-01)

The Efficacy and Safety of Sofosbuvir Containing Regimen in the Treatment of Hcv Infection in Patients with Haemoglobinopathy
by: Nawfal R Hussein
Published: (2017-01-01)

Efficacy and tolerability of sofosbuvir and daclatasvir for treatment of hepatitis C genotype 1 & 3 in patients undergoing hemodialysis- a prospective interventional clinical trial
by: Shafiq Ur Rehman Cheema, et al.
Published: (2019-11-01)

Effectiveness of chronic hepatitis C treatment with direct-acting antivirals in the Public Health System in Brazil
by: Iandra Holzmann, et al.

Efficacy of daclatasvir plus peginterferon alfa and ribavirin for patients with chronic hepatitis C genotype 4 infection
by: Hussien Ahmed, et al.
Published: (2017-03-01)

Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia
by: Tengiz Tsertsvadze, et al.
Published: (2020-01-01)

Response of Sofosbuvir and Daclatasvir combination in Chronic Hepatitis C with Hemodialysis Pakistani Patients: A Single Centre Study
by: Rahmat Ali Khan, et al.
Published: (2018-12-01)

Validated Reversed-Phase Liquid Chromatographic Method with Gradient Elution for Simultaneous Determination of the Antiviral Agents: Sofosbuvir, Ledipasvir, Daclatasvir, and Simeprevir in Their Dosage Forms
by: Essam Ezzeldin, et al.
Published: (2020-10-01)

Prescription and efficacy of daclatasvir and sofosbuvir ± ribavirin for hepatitis C infection, including patient-reported outcomes, in routine practice in three European countries: The CMPASS-EU cohort study
by: Stefan Bourgeois, et al.
Published: (2020-01-01)

Assessing the impact of a combination of sofosbuvir and daclatasvir treatment for hepatitis C virus infection on heart rate, rhythm and heart rate variability using 24-hour ECG monitoring
by: Ahmed Mohamed El Missiri, et al.
Published: (2020-07-01)

Virological and Clinical Outcome of DAA Containing Regimens in a Cohort of Patients in Calabria Region (Southern Italy)
by: Vincenzo Scaglione, et al.
Published: (2020-02-01)

Specific, highly sensitive and simple spectrofluorimetric method for quantification of daclatasvir in HCV human plasma patients and in tablets dosage form
by: Ali Ramadan, et al.
Published: (2019-02-01)

Sofosbuvir and daclatasvir are safe and effective in treatment of recurrent hepatitis C virus in Egyptian patients underwent living donor liver transplantation
by: Osama Aboelfotoh Aly, et al.
Published: (2020-09-01)

Treatment of hepatitis C virus infection in the future
by: Tatsuo Kanda, et al.
Published: (2013-12-01)

Evaluation of cardiac function by global longitudinal strain before and after treatment with sofosbuvir-based regimens in HCV infected patients
by: Maria Mazzitelli, et al.
Published: (2018-10-01)

Reactivation of herpesvirus in patients with hepatitis C treated with direct-acting antiviral agents
by: Ghweil AA, et al.
Published: (2019-04-01)

Sofosbuvir-Based Therapies Achieved Satisfactory Virological Response in Chinese Individuals with Genotypes 3 and 6 Infections: A Real-World Experience
by: Tang Q, et al.
Published: (2021-06-01)

Risk Factors for Liver Decompensation and HCC in HCV-Cirrhotic Patients after DAAs: A Multicenter Prospective Study
by: Filomena Morisco, et al.
Published: (2021-07-01)